These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21812862)

  • 41. High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.
    Messori A; Peyvandi F; Trippoli S; Palla R; Rosendaal FR; Mannucci PM
    Blood Transfus; 2018 Feb; 16(2):215-220. PubMed ID: 28686156
    [No Abstract]   [Full Text] [Related]  

  • 42. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.
    Knight C; Paisley S; Wight J; Jones ML
    Haemophilia; 2003 Jul; 9(4):521-40. PubMed ID: 12828681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world resource use and costs of haemophilia A-related bleeding.
    Shrestha A; Eldar-Lissai A; Hou N; Lakdawalla DN; Batt K
    Haemophilia; 2017 Jul; 23(4):e267-e275. PubMed ID: 28574162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.
    Chang H; Sher GD; Blanchette VS; Teitel JM
    Haemophilia; 1999 Jul; 5(4):247-52. PubMed ID: 10469178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
    Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
    Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
    Walsh CE; Valentino LA
    Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
    Nakar C; Cooper DL; DiMichele D
    Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
    Schneiderman J; Nugent DJ; Young G
    Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    Hedner U
    Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
    Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
    Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
    Young G; Auerswald G; Jimenez-Yuste V; Lambert T; Morfini M; Santagostino E; Blanchette V
    Thromb Res; 2012 Dec; 130(6):864-70. PubMed ID: 22964026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surgery--a challenge in haemophiliacs with inhibitors.
    Serban M; Poenaru D; Pop L; Ionita H; Mihailov MD; Tepeneu N; Bădeţi R; Lighezan D; Schramm W
    Hamostaseologie; 2009 Oct; 29 Suppl 1():S39-41. PubMed ID: 19763345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
    Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
    Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
    Ekert H; Brewin T; Boey W; Davey P; Tilden D
    Haemophilia; 2001 May; 7(3):279-85. PubMed ID: 11380632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hemophilia. Treatment of patients with inhibitors: cost issues.
    Goudemand J
    Haemophilia; 1999 Nov; 5(6):397-401. PubMed ID: 10583526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.